UroGen Pharma Ltd. (URGN)
NASDAQ: URGN · Real-Time Price · USD
4.170
-3.370 (-44.69%)
At close: May 21, 2025, 4:00 PM
4.000
-0.170 (-4.08%)
Pre-market: May 22, 2025, 8:09 AM EDT
UroGen Pharma Employees
UroGen Pharma had 235 employees as of December 31, 2024. The number of employees increased by 34 or 16.92% compared to the previous year.
Employees
235
Change (1Y)
34
Growth (1Y)
16.92%
Revenue / Employee
$390,940
Profits / Employee
-$589,068
Market Cap
192.27M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
URGN News
- 17 hours ago - UroGen Pharma: ODAC Decision Puts Drug Approval In Limbo, But It's Not Over, Either - Seeking Alpha
- 19 hours ago - UroGen Announces Outcome of Oncologic Drugs Advisory Committee for UGN-102 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC) - Business Wire
- 22 hours ago - Bronstein, Gewirtz & Grossman, LLC Encourages UroGen Pharma Ltd. (URGN) Investors to Inquire about Securities Investigation - Accesswire
- 1 day ago - Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against UroGen Pharma Ltd. (URGN) And Encourages Investors to Reach Out - Accesswire
- 2 days ago - Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against UroGen Pharma Ltd. (URGN) And Encourages Stockholders to Reach Out - Accesswire
- 9 days ago - UroGen Pharma Ltd. (URGN) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 10 days ago - UroGen Pharma Reports First Quarter 2025 Financial Results and Provides a Business Update - Business Wire
- 14 days ago - UroGen Announces FDA Advisory Committee for UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer - Business Wire